{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=39",
    "query": {
      "condition": "Recombinant",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1029,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T11:27:14.715Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03876301",
      "title": "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorder",
        "Blood Coagulation Disorders, Inherited",
        "Coagulation Protein Disorders",
        "Hemophilia A",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Hematologic Diseases",
        "Hemorrhagic Disorders",
        "Factor VIII Deficiency"
      ],
      "interventions": [
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-01-21",
      "completion_date": "2023-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876301"
    },
    {
      "nct_id": "NCT01009905",
      "title": "An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Growth Hormone Disorder",
        "Pituitary Dwarfism",
        "Hypopituitarism"
      ],
      "interventions": [
        {
          "name": "somatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 22960,
      "start_date": "2002-06-24",
      "completion_date": "2016-09-30",
      "has_results": false,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 1,
      "location_summary": "Plainsboro, New Jersey",
      "locations": [
        {
          "city": "Plainsboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009905"
    },
    {
      "nct_id": "NCT05789745",
      "title": "A Study to Evaluate Plasma Gelsolin in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Volunteers",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Recombinant human plasma gelsolin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "BioAegis Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-03-14",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789745"
    },
    {
      "nct_id": "NCT02307851",
      "title": "Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Quadrivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator TIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 400,
      "start_date": "2014-11",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307851"
    },
    {
      "nct_id": "NCT00357656",
      "title": "Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Protein-Free Factor VIII (rAHF-PFM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 85,
      "start_date": "2006-05-29",
      "completion_date": "2015-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357656"
    },
    {
      "nct_id": "NCT00000857",
      "title": "A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Interleukin-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 65,
      "start_date": null,
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000857"
    },
    {
      "nct_id": "NCT07453888",
      "title": "Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Arteritic Anterior Ischemic Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "Cenegermin",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 272,
      "start_date": "2026-07-01",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 27,
      "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07453888"
    },
    {
      "nct_id": "NCT00002796",
      "title": "Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "sodium phenylbutyrate",
          "type": "DRUG"
        },
        {
          "name": "indomethacin",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 46,
      "start_date": "1997-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002796"
    },
    {
      "nct_id": "NCT01913444",
      "title": "Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neonates on ECMO"
      ],
      "interventions": [
        {
          "name": "Recombinant Antithrombin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "1 Minute to 30 Days"
      },
      "enrollment_count": 0,
      "start_date": "2013-07",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-01-13",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01913444"
    },
    {
      "nct_id": "NCT00126724",
      "title": "Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid",
        "Arthritis, Psoriatic",
        "Ankylosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "tgAAC94 gene therapy vector",
          "type": "GENETIC"
        },
        {
          "name": "tgAAC94 placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Targeted Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2005-08",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2009-07-29",
      "last_synced_at": "2026-10-28T11:27:14.715Z",
      "location_count": 22,
      "location_summary": "Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126724"
    }
  ]
}